Our findings document the ability of low-dose RT to upregulate the expression of FAS and TRAIL-R2 on the surface of human CD19-expressing ALL cells, in vitro and in vivo (Figs. 1, 2). The gene discussed is TNFRSF10B; the disease is acute lymphoblastic leukemia.